2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
15
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Endometrial Neoplasms
2
Solid Tumors
1
PIK3CA-Mutated Cancers
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Metastatic Castration-Resistant Prostate Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Unresectable or Metastatic Solid Malignancy
×
inavolisib
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts